《新股表現》清晰醫療(01406.HK)暗盤高開近19%報1.9元
根據輝立交易平臺顯示,明天掛牌的清晰醫療集團(01406.HK)暗盤高開近19%報1.9元欠承接,現報1.6元,持平於上市價1.6元,成交134萬股。
清晰是一家眼科專科私營醫療機構。是次上市共發售1.36億股,其中10%公開發售獲5.17倍超購,認購一手中籤率40%,股份以招股範圍(1.6-3元)下限定價,料集資淨額約1.77億元,其中約44.8%用在香港成立兩家新眼科醫療中心;約30.5%用作收購大灣區內一至兩家眼科診所、眼科門診部或眼科醫院權益;約14.7%用作與合作夥伴在中國設立眼科診所。上市獨家保薦人光大證券。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.